hrcak mascot   Srce   HID

Izvorni znanstveni članak
https://doi.org/10.13112/PC.2014.3

Urolithiasis – a potential complication of ceftriaxone therapy

Daniel Turudić ; Medicinski fakultet Sveučilišta u Zagrebu, 10000 Zagreb
Danica Batinić ; Medicinski fakultet Sveučilišta u Zagrebu, Klinički bolnički centar Zagreb, Zavod za nefrologiju, dijalizu i transplantaciju, 10000 Zagreb
Branko Miše ; Zavod za dječje zarazne bolesti, Sveučilište u Zagrebu, 10000 Zagreb
Ivan Habuš ; Odjel za fi zikalnu kemiju Instituta „Ruđer Bošković“, 10000 Zagreb
Marija Spajić ; Opća bolnica Karlovac, Karlovac
Goran Krnjak ; Medicinski fakultet Sveučilišta u Zagrebu, Klinički bolnički centar Zagreb, Zavod za nefrologiju, dijalizu i transplantaciju, 10000 Zagreb
Danko Milošević ; Medicinski fakultet Sveučilišta u Zagrebu, Klinički bolnički centar Zagreb, Zavod za nefrologiju, dijalizu i transplantaciju, 10000 Zagreb

Puni tekst nije dostupan.

Sažetak
A cohort of 238 children diagnosed with cystopyelonephritis were retrospectively analyzed in 2011 to assess the possible ceftriaxone
risk of urinary stone formation. All children were treated with ceftriaxone in a standard dosage of 60 mg/kg/day for 10 days. Urinary
tract imaging revealed anomalies in 73, vesicoureteral refl ux in 66 and hydronephrosis in 7 children. No ceftriaxone stone formation
and no sign of abdominal colic or macro/microhematuria was found during one-month monitoring. Ceftriaxone administration is
quite safe in the usual dosage of 60 mg/kg/24 h for 10 days. Caution is only warranted in children requiring higher dosage of ≥100
mg/kg/24 h and prolonged administration. In such cases, we recommend ultrasound of urinary tract and gallbladder screening for
hypercalciuria and alkalization of urine.

Ključne riječi
ceftriaxone; urinary calculi; urinary tract infections

Hrčak ID: 119997

URI
https://hrcak.srce.hr/119997

[hrvatski]

Posjeta: 404 *